BACKGROUND AND OBJECTIVE: Mixing different drugs for use in continuous infusion systems is a common practice in palliative care, but analytical study of compatibility and stability is not always available. The objective of this work is to study the stability of solutions of ondansetron and haloperidol at different concentrations and temperatures all prepared in 0.9% NaCl and stored in infusors, with all cases protected from light. MATERIALS AND METHODS: The high performance liquid chromatography-Ultraviolet (HPLC-UV) method was employed for the determination of the drugs. The concentrations of the admixtures were 0.15-0.25 mg/mL and 0.3-0.4 mg/mL of haloperidol and ondansetron, respectively, with a storage temperature of 25°C and 37°C. RESULTS: All solutions were initially clear and colourless, but visible particles appear, in all cases, into the infusers after 2 days since their preparation. CONCLUSION: From the results obtained we can conclude that the mixtures prepared in the conditions previously described are stable less than 48 hours.
BACKGROUND AND OBJECTIVE: Mixing different drugs for use in continuous infusion systems is a common practice in palliative care, but analytical study of compatibility and stability is not always available. The objective of this work is to study the stability of solutions of ondansetron and haloperidol at different concentrations and temperatures all prepared in 0.9% NaCl and stored in infusors, with all cases protected from light. MATERIALS AND METHODS: The high performance liquid chromatography-Ultraviolet (HPLC-UV) method was employed for the determination of the drugs. The concentrations of the admixtures were 0.15-0.25 mg/mL and 0.3-0.4 mg/mL of haloperidol and ondansetron, respectively, with a storage temperature of 25°C and 37°C. RESULTS: All solutions were initially clear and colourless, but visible particles appear, in all cases, into the infusers after 2 days since their preparation. CONCLUSION: From the results obtained we can conclude that the mixtures prepared in the conditions previously described are stable less than 48 hours.
Authors: Francisco Fernandez-Campos; Mireia Mallandrich; Ana C Calpena; Ana Ayestarán; Carmen Lacasa Journal: J Pharm Pharmacol Date: 2013-01-14 Impact factor: 3.765
Authors: Andrew Dickman; Matthew Bickerstaff; Richard Jackson; Jennifer Schneider; Stephen Mason; John Ellershaw Journal: BMC Palliat Care Date: 2017-03-23 Impact factor: 3.234